MedTrace Logo

Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

NCT02092389 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2017-02-23

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to explore the fecal calprotectin (fC) levels of UC patients under adalimumab therapy and the correlation with their general wellbeing (Quality of Life \[QoL\]), workability, and disease activity.

Conditions

  • Moderate to Severe Ulcerative Colitis

Sponsors & Collaborators

Principal Investigators

  • Alexander Dorr, MD · AbbVie Austria

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-10-31
Completion
2016-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02092389 on ClinicalTrials.gov